title: A novel biweekly multidrug regimen of gemcitabine, oxaliplatin, 5-fluorouracil (5-FU), and folinic acid (FA) in pretreated patients with advanced colorectal carcinoma.
abstract: Previous results suggest that GEM affects 5-fluorouracil (5-FU) metabolism and pharmacokinetics in cancer patients, while combined with oxaliplatin, levo-folinic acid, and 5-FU (GOLF regimen), at doses achievable in cancer patients, determines high cytotoxic and proapoptotic antitumour activity in colon cancer cells in vitro. On these bases we designed a phase I-II clinical trial testing the GOLF regimen in patients with metastatic colorectal carcinoma, who had received at least a prior line of chemotherapy. In total, 29 patients (20 males and nine females) enrolled in the study received every 2 weeks, gemcitabine (patients #1-3 received 600 mg m(-2); patients # 4-6 received 850 mg m(-2); while patients # 7-29 received 1000 mg m(-2)) on the day 1, levo-folinic acid (100 mg m(-2)) on the days 1 and 2; 5-fluorouracil (400 mg m(-2)) in bolus injection, followed by a 22-h continuous infusion (800 mg m(-2)) on the days 1 and 2, and oxaliplatin (85 mg m(-2)), 6 h after the 5-FU bolus on day 2. The most frequent side effect was grade I-II haematological toxicity. In total, 28 patients were evaluable for response: three achieved a complete response, nine a partial response, 10 had a stable disease, and six progressed. The average time to progression and overall survival of the patients was, respectively, 7.26 and 22 months. Our GOLF combination is well tolerated and seems promising for the treatment of advanced colorectal cancer.
authors.affiliation: Section of Oncology, Human Pathology and Oncology Department, University of Siena School of Medicine, Viale Bracci 11, Siena 53100, Italy.
authors.forename: P
authors.initials: P
authors.lastname: Correale
authors.forename: S
authors.initials: S
authors.lastname: Messinese
authors.forename: M
authors.initials: M
authors.lastname: Caraglia
authors.forename: S
authors.initials: S
authors.lastname: Marsili
authors.forename: A
authors.initials: A
authors.lastname: Piccolomini
authors.forename: R
authors.initials: R
authors.lastname: Petrioli
authors.forename: F
authors.initials: F
authors.lastname: Ceciarini
authors.forename: L
authors.initials: L
authors.lastname: Micheli
authors.forename: C
authors.initials: C
authors.lastname: Nencini
authors.forename: A
authors.initials: A
authors.lastname: Neri
authors.forename: G
authors.initials: G
authors.lastname: Vuolo
authors.forename: A
authors.initials: A
authors.lastname: Guarnieri
authors.forename: A
authors.initials: A
authors.lastname: Abbruzzese
authors.forename: S D
authors.initials: SD
authors.lastname: Prete
authors.forename: G
authors.initials: G
authors.lastname: Giorgi
authors.forename: G
authors.initials: G
authors.lastname: Francini
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000009:adverse effects; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D003841:Deoxycytidine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D004334:Drug Administration Schedule; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D002955:Leucovorin / Q000008:administration & dosage / Q000009:adverse effects; D008297:Male; D020714:Maximum Tolerated Dose; D008875:Middle Aged; D009944:Organoplatinum Compounds / Q000008:administration & dosage / Q000009:adverse effects; D000077150:Oxaliplatin; D015996:Survival Rate; D016896:Treatment Outcome; D000093542:Gemcitabine
chemical_list: D000970:Antineoplastic Agents; D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D003841:Deoxycytidine; D002955:Leucovorin; D005472:Fluorouracil; D000093542:Gemcitabine